PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients.

Kerrie CloverSylvie D LambertChristopher OldmeadowBenjamin BrittonMadeleine T KingAlex J MitchellGregory Carter

Published in: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2018)

The convergent and criterion validity of the PROMIS depression measures in cancer populations was confirmed, although the optimal cut-off points are not established. PROMIS measures were briefer than BDI-II and CES-D but do not offer any advance in terms of diagnostic accuracy, reduced response burden or cost over other legacy measures of depression in oncology patients.

Keyphrases

depressive symptoms
patient reported outcomes
sleep quality
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
squamous cell carcinoma
papillary thyroid
prognostic factors
peritoneal dialysis
young adults
lymph node metastasis
squamous cell